Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TELO
Upturn stock ratingUpturn stock rating

Telomir Pharmaceuticals, Inc. Common Stock (TELO)

Upturn stock ratingUpturn stock rating
$1.57
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TELO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit -45.26%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 45.54M USD
Price to earnings Ratio -
1Y Target Price 15.5
Price to earnings Ratio -
1Y Target Price 15.5
Volume (30-day avg) -
Beta -
52 Weeks Range 1.52 - 8.40
Updated Date 06/29/2025
52 Weeks Range 1.52 - 8.40
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.4

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -391.62%
Return on Equity (TTM) -872.57%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 46827162
Price to Sales(TTM) -
Enterprise Value 46827162
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 29762700
Shares Floating 17618311
Shares Outstanding 29762700
Shares Floating 17618311
Percent Insiders 34.17
Percent Institutions 12.53

ai summary icon Upturn AI SWOT

Telomir Pharmaceuticals, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on developing and commercializing therapies to address age-related diseases and conditions, including cardiovascular, metabolic and neurodegenerative conditions. The company's lead product is Telomir-1, a small molecule compound.

business area logo Core Business Areas

  • Drug Development: Focused on developing and commercializing Telomir-1, a small molecule compound targeting age-related diseases.

leadership logo Leadership and Structure

The company has a management team leading its development efforts. Details of the specific structure can be found on its investor relations website or SEC filings.

Top Products and Market Share

overview logo Key Offerings

  • Telomir-1: Telomir-1 is their lead product candidate, a small molecule compound aimed at treating age-related diseases. It is in the pre-clinical stage. Competitors are other companies developing therapies for age-related diseases.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is competitive and heavily regulated. Demand for treatments for age-related diseases is increasing due to the aging global population.

Positioning

Telomir Pharmaceuticals is positioned as a company developing innovative therapies in the age-related disease space. Being pre-clinical, it faces competition from larger, more established pharmaceutical companies with existing products or late-stage clinical trials.

Total Addressable Market (TAM)

The TAM for age-related disease therapeutics is substantial, potentially in the hundreds of billions of dollars. Telomir Pharmaceuticals' position depends on the successful development and commercialization of Telomir-1.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach
  • Focus on unmet medical needs
  • Experienced management team (needs verification from source documents)

Weaknesses

  • Pre-clinical stage of development
  • Limited financial resources
  • Dependence on single drug candidate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Expansion into new therapeutic areas

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Inability to raise sufficient capital

Competitors and Market Share

competitor logo Key Competitors

  • CRISPR Therapeutics (CRSP)
  • BioAge Labs
  • Unity Biotechnology (UBX)

Competitive Landscape

Telomir Pharmaceuticals faces competition from both established pharmaceutical companies and other biotech firms focusing on age-related diseases. Its competitive advantage hinges on the novelty and efficacy of its therapeutic approach.

Growth Trajectory and Initiatives

Historical Growth: There is no historical growth to report for sales. The company is pre-revenue. Growth depends on successful development of drug candidate

Future Projections: Future growth projections depend on the successful development and commercialization of Telomir-1 and other potential drug candidates. Analyst estimates would need to be consulted.

Recent Initiatives: Recent strategic initiatives would include clinical trial preparations, fundraising activities, and partnerships. Refer to latest news releases.

Summary

Telomir Pharmaceuticals is a pre-clinical stage company targeting age-related diseases with a novel therapeutic approach. Its success depends on the successful development and commercialization of Telomir-1 and securing funding. Its weaknesses are its pre-clinical status and limited resources, which must be balanced against the opportunities in the growing market for aging-related therapeutics. Telomir Pharmaceuticals must successfully navigate regulatory hurdles, competition, and funding challenges to realize its growth potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings (10-K, 10-Q)
  • Press releases
  • Third-party financial data providers

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Financial data may be outdated. Consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Telomir Pharmaceuticals, Inc. Common Stock

Exchange NASDAQ
Headquaters Miami, FL, United States
IPO Launch date 2024-02-09
Chairman of the Board & CEO Mr. Erez Aminov
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.